Get the latest tech news
Trial results for new lung cancer drug are 'off the charts'
More than half of patients with advanced forms of disease who took lorlatinib were still alive after five years with no progression
The results are the longest progression-free survival (PFS) outcomes ever recorded in patients with non-small cell lung cancer, the world’s most common form of the disease. “To our knowledge these results are unprecedented,” said the study’s lead author, Dr Benjamin Solomon, a medical oncologist at the Peter MacCallum Cancer Centre in Melbourne, Australia. Dr David Spigel, the chief scientific officer of the Sarah Cannon Research Institute in London, a world-leading clinical trials facility specialising in new therapies for cancer patients, welcomed the findings.
Or read this on Hacker News
